Diferansiye tiroid kanserlerinde nötrofil/lenfosit oranı ve monosit/yüksek dansiteli lipoprotein kolesterol oranının araştırılması

Year 2020, Volume: 3 Issue: 2, 172 - 175, 19.03.2020

Kenan Çadırcı , Faruk Yıldız Havva Keskın Muharrem Bayrak , Hilal Kiziltunc Ozmen , Şenay Arıkan Durmaz , Ayşe Çarlıoğlu

https://doi.org/10.32322/jhsm.689142

Cited By: 1

Abstract

ÖZ
Amaç: Tiroid kanserleri endokrin kökenli en yaygın malign tümörlerdir. Tiroid kanserleri histopatolojik ve klinik davranışlara göre sınıflandırılır. Papiller ve foliküler kanserler diferansiye tiroid kanserleri (DTK) olarak sınıflandırılırlar. Son zamanlarda nötrofil/lenfosit oranı (NLO) ve monosit/yüksek dansiteli lipoprotein kolesterol oranı (MHO) oksidatif stres ve sistemik inflamasyonun güçlü göstergeleri olduğu ve MHO’ nun koroner ateroskleroz ile ilişkili koroner kalp hastalığında mortalitenin güçlü göstergeleri olduğu ortaya konuldu. Bu çalışmamızda DTK tanısı konulmuş olan hastalarımızda bu belirteçleri değerlendirmeyi amaçladık.
Gereç ve Yöntem: Çalışmamıza DTK tanısı yeni konulan 125 hasta ve tamamen sağlıklı kişilerden oluşan 75 kişi kontrol grubu olarak dahil edildi. Hasta ve kontrol grubunun 12 saatlik açlık sonrası kolesterol parametreleri ve hematolojik parametreleri çalışılarak değerlendirmeye alındı. NLO ve MHO değerleri SPSS kullanılarak manuel olarak hesaplandı.
Bulgular: Hasta ve sağlıklı grubun sırası ile NLO ortalaması (3,2±2,8 ve 2,4±1,3 p=0,013) ve MHO (0,038±0,052 ve 0,102±0,079 p=0,0000) şeklinde tespit edildi ve aralarında istatistiki açıdan anlamlı bir fark olduğu tespit edildi. Yapılan korelasyon analizinde ise NLO ile sırası ile beyaz küre (r=0,530, p<0,001), nötrofil ( r=0,293, p<0,001) ve CRP (r=0,371, p=0,005) arasında pozitif korelasyon tespit edilirken NLO ile lenfosit arasında (r=-0,271, p=0,001) negatif korelasyon tespit edildi.
Sonuç: Bu çalışma ile elde edilen verilere göre diferansiye tiroid kanserlerinin sistemik inflamasyonu artırdığı gözlenmektedir.

Supporting Institution

YOK

Project Number

YOK

Investigation of the neutrophil/lymphocyte and monocyte to high-density lipoprotein cholesterol ratios in differentiated thyroid cancers

Abstract

ABSTRACT
Introduction: Thyroid cancers are the most common malignant tumors of endocrine origin. They are classified depending on their histopathological and clinical behaviors. Papillary and follicular cancers are classified as differentiated thyroid carcinomas (DTCs). The neutrophil/lymphocyte ratio (NLR) and the monocyte to high-density lipoprotein cholesterol ratio (MHR) have recently been shown to be powerful markers of oxidative stress and systemic inflammation, and the MHR has been revealed as a potent marker of mortality in coronary heart disease associated with coronary atherosclerosis. The aim of this study was to evaluate these markers in patients diagnosed with DTC.
Material and Method: One hundred twenty-five patients newly diagnosed with DTC and a 75-member control group consisting of entirely healthy individuals were included in the study. The patient and control groups were evaluated by investigation of cholesterol and hematological parameters following 12-h fasting. MHR and NLR values were calculated manually on SPSS software.
Results: Significant differences were determined between the patient and control groups in terms of mean NLR (3.2±2.8 vs 2.4±1.3, respectively, p=0.013) and MHR (0.038±0.052 vs 0.102±0.079, respectively, p=0.0000) values. In the correlation analysis, positive correlation was determined between the NLR and white cell count (r=0.530, p<0.001), neutrophil count (r=0.293, p<0.001) and CRP (r=0.371, p=0.005), while negative correlation was determined between the NLR and lymphocyte count (r=-0.271, p=0.001).
Conclusion: The study data show that DTCs increase systemic inflammation.

Keywords

Differentiated thyroid carcinoma, neutrophil/lymphocyte ratio, monocyte to high-density lipoprotein cholesterol ratio

Project Number

YOK

References

• 1-Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA. Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits 2015;8(1):30–40
• 2-Grimm D. Current knowledge in thyroid cancer—from bench to bedside. Int J Mol Sci 2017; 18(7): 1529. doi: 10.3390/ijms18071529
• 3- Shah JP. Thyroid carcinoma: epidemiology, histology, and diagnosis. Clin Adv Hematol Oncol 2015;13(4 Suppl 4):3–6.
• 4-Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid 2013;23(7):885-91. doi: 10.1089/thy.2013.0045.
• 5-Gonda TA, Tu S, Wang TC. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle 2009; 8(13):2005-13. doi: 10.4161/cc.8.13.8985
• 6-Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med 2019;18(3):121-6. doi: 10.4103/aam.aam_56_18.
• 7-Rho MH, Kim DW, Hong HP, et al. Diagnostic value of antithyroid peroxidase antibody for incidental autoimmune thyroiditis based on histopathologic results. Endocrine 2012;42(3):647-52. doi: 10.1007/s12020-012-9695-y.
• 8-Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg 2007; 201(5): 764-5.
• 9-Tang H, Lu W, Li B, Li C, Xu Y, Dong J. Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis. Oncotarget 2017;8(22):36857-68. doi: 10.18632/oncotarget.16143.
• 10-Miyatani K, Saito H, Kono Y, et al. Combined analysis of the pre- and postoperative neutrophil-lymphocyte ratio predicts the outcomes of patients with gastric cancer. Surg Today 2018;48(3):300-7. doi: 10.1007/s00595-017-1587-6.
• 11-Satomi A, Murakami S, Ishida K, Mastuki M, Hashimoto T, Sonoda M. Significance of increased neutrophils in patients with advanced colorectal cancer. Acta Oncol 1995;34(1):69-73. doi: 10.3109/02841869509093641
• 12-Ganjali S, Gotto AM Jr, Ruscica M, et al. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases. J Cell Physiol 2018;233(12):9237-46. doi: 10.1002/jcp.27028. Epub 2018 Aug 4.
• 13-Hussain T, Tan B, Yin Y, Blachier F, Tossou MC, Rahu N. Oxidative stress and inflammation: what polyphenols can do for us? Oxid Med Cell Longev 2016;2016:7432797. doi: 10.1155/2016/5698931
• 14- Biswas SK. Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox? Oxid Med Cell Longev. 2016; 2016: 5698931. doi: 10.1155/2016/569931
• 15- Tsalamandris S, Antonopoulos AS, Oikonomou E, et al. The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol 2019; 14(1): 50-9. doi: 10.15420/ecr.2018.33.1.
• 16-Lopez-Candales A, Hernández Burgos PM, Hernandez-Suarez DF, Harris D. Linking chronic inflammation with cardiovascular disease: from normal aging to the metabolic syndrome. J Nat Sci. 2017;3(4). pii: e341.
• 17-Moldoveanu B, Otmishi P, Jani P, et al. Inflammatory mechanisms in the lung. J Inflamm Res 2009;2:1-11.
• 18-Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol 2012;2:98. doi: 10.3389/fimmu.2011.00098.
• 19-Fugazzola L, Colombo C, Perrino M, Muzza M. Papillary thyroid carcinoma and inflammation. Front Endocrinol (Lausanne) 2011;2:88. doi:10.3389/fendo.2011.00088
• 20-Guarino V, Castellone MD, Avilla E, Melillo RM. Thyroid cancer and inflammation. Mol Cell Endocrinol 2010;321(1):94-102. doi: 10.1016/j.mce.2009.10.003.
• 21- Muzza M, Colombo C, Cirello V, Perrino M, Vicentini L, Fugazzola L. Oxidative stress and the subcellular localization of the telomerase reverse transcriptase (TERT) in papillary thyroid cancer. Mol Cell Endocrinol 2016;431:54-61. doi: 10.1016/j.mce.2016.05.005.
• 22- Kocer D, Karakukcu C, Karaman H, Gokay F, Bayram F. May the neutrophil/lymphocyte ratio be a predictor in the differentiation of different thyroid disorders? Asian Pac J Cancer Prev 2015;16(9):3875-9.
• 23- Ceylan Y, Kumanlıoğlu K, Oral A, Ertan Y, Özcan Z. The correlation of clinicopathological findings and neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in Papillary thyroid carcinoma. Mol Imaging Radionucl Ther 2019;28(1):15-20. doi: 10.4274/mirt.galenos.2018.60490.
• 24-Manatakis DK, Tseleni-Balafouta S, Balalis D, Soulou VN, et al. Association of baseline neutrophil-to-lymphocyte ratio with clinicopathological characteristics of papillary thyroid carcinoma.Int J Endocrinol 2017;2017:8471235. doi: 10.1155/2017/8471235.
• 25- Lee F, Yang PS, Chien MN, Lee JJ, Leung CH, Cheng SP. An increased neutrophil-to-lymphocyte ratio predicts incomplete response to therapy in differentiated thyroid cancer. Int J Med Sci 2018;15(14):1757-63. doi: 10.7150/ijms.28498. eCollection 2018.